152 results on '"Tolar, Martin"'
Search Results
2. Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
3. The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention
4. APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics.
5. Reduction of Hippocampal Atrophy and Lateral Ventricle Enlargement Correlates with Clinical Benefit in APOE4 Carriers with Early AD: 1‐Year Results from a Phase 2 Biomarker Study with Oral Anti‐Amyloid Oligomer Inhibitor ALZ‐801
6. Prevalence of Cerebral Microhemorrhages and Cortical Superficial Siderosis in APOE4/4 Homozygotes with Early Alzheimer’s disease: Baseline Findings from Phase 3 Trial of Oral ALZ‐801 in APOE4/4 Homozygotes (APOLLOE4)
7. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
8. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
9. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
10. Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate) (P5-6.003)
11. Effects of ALZ-801, an Oral Amyloid Oligomer Inhibitor, on Biomarkers of Alzheimer’s Disease (AD): 12-Month Results of Phase 2 Biomarker Study in Early AD (S26.007)
12. Effects of Oral ALZ‐801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer’s Disease: Results of Six‐month Interim Analysis from a Phase 2 Biomarker Study
13. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data
14. WITHDRAWN: The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis
15. Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
16. Labor vs Liberal: do the markets care? [Revised version of a paper presented at the Conference of Economists (24th: 1995: Adelaide)]
17. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
18. Selective Continuous Flow Iodination Guided by Direct Spectroscopic Observation of Equilibrating Aryl Lithium Regioisomers
19. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
20. Spatial navigation testing discriminates two types of amnestic mild cognitive impairment
21. A behavioral model of nondurable consumption expenditure
22. Imaging is superior to cognitive testing for early diagnosis of Alzheimer’s disease
23. P1‐043: INHIBITION OF AMYLOID OLIGOMER FORMATION BY ENDOGENOUS METABOLITE OF ALZ‐801/TRAMIPROSATE IN THE HUMAN BRAIN: DISCOVERY AND CHARACTERIZATION OF 3‐SPA IN NORMAL SUBJECTS AND ALZHEIMER'S DISEASE PATIENTS
24. Kilogram-Scale Synthesis of the CXCR4 Antagonist GSK812397
25. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
26. [P1-052]: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4 HOMOZYGOTES WITH MILD TO MODERATE ALZHEIMER'S DISEASE (AD) ARE SUSTAINED OVER 130 WEEKS: RESULTS OF A PHASE 3 EXTENSION STUDY
27. ALZ-801 MECHANISM OF ACTION: STOICHIOMETRY OF BETA AMYLOID ANTI-OLIGOMER EFFECT, PK/PD, AND CLINICAL DOSE SELECTION FOR CONFIRMATORY PHASE 3 PROGRAM IN ALZHEIMER’S DISEASE
28. NOVEL ENVELOPING MECHANISM OF ACTION OF ALZ-801: CONFORMATIONAL STABILIZATION OF BETA AMYLOID BY A SMALL MOLECULE RESULTS IN ANTI-OLIGOMER ACTIVITY
29. US immigration order strikes against biotech
30. INHIBITION OF AMYLOID OLIGOMER FORMATION BY ENDOGENOUS METABOLITE OF ALZ-801/TRAMIPROSATE IN THE HUMAN BRAIN: DISCOVERY AND CHARACTERIZATION OF 3-SPA IN NORMAL SUBJECTS AND ALZHEIMER’S DISEASE PATIENTS
31. Úmrtnost seniorů na vnější příčiny smrti v České republice v letech 1994 až 2012
32. An Efficient, Scalable Synthesis of the HIV Reverse Transcriptase Inhibitor Ziagen® (1592U89)
33. Synthesis of Ultra-Short-Acting Neuromuscular Blocker GW 0430: A Remarkably Stereo- and Regioselective Synthesis of Mixed Tetrahydroisoquinolinium Chlorofumarates
34. P2-012: Phase 1 Development of ALZ-801, a Novel Beta Amyloid Anti-Aggregation Prodrug of Tramiprosate with Improved Drug Properties, Supporting Bridging to The Phase 3 Program
35. Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous ad patients: efficacy and safety analyses from two Phase 3 trials
36. Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate ad: combined sub-group analyses from two Phase 3 trials
37. Open air palladium catalyzed cyanation—the use of PMHS to protect from oxygen
38. Direct synthesis of thioethers from sulfonyl chlorides and activated alcohols
39. ChemInform Abstract: An Efficient, Scalable Synthesis of the HIV Reverse Transcriptase Inhibitor Ziagen® (1592U89)
40. ChemInform Abstract: Direct Synthesis of Thioethers from Sulfonyl Chlorides and Activated Alcohols
41. CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4 HOMOZYGOTES WITH MILD TO MODERATE ALZHEIMER'S DISEASE (AD) ARE SUSTAINED OVER 130 WEEKS: RESULTS OF A PHASE 3 EXTENSION STUDY
42. Open Air Palladium-Catalyzed Cyanation — The Use of PMHS to Protect from Oxygen
43. Practical Acid-Catalyzed Acylation of Sulfonamides with Carboxylic Acid Anhydrides
44. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys
45. Synthesis of Steroid 'Antedrugs' for Evaluation as Safe Treatments for Asthma: Practical Synthesis of the Inhaled Steroid GR250495X
46. PHASE 1 DEVELOPMENT OF ALZ-801, A NOVEL BETA AMYLOID ANTI-AGGREGATION PRODRUG OF TRAMIPROSATE WITH IMPROVED DRUG PROPERTIES, SUPPORTING BRIDGING TO THE PHASE 3 PROGRAM
47. P3-085: APOE ∊4 affects visual memory binding in amnestic mild cognitive impairment
48. Spatial Navigation and APOE in Amnestic Mild Cognitive Impairment
49. P2-145: Spatial navigation computer test can discriminate two types of amnestic mild cognitive impairment
50. P3-053: APOE E4 affects spatial working memory and attention in patients with amnestic mild cognitive impairment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.